SCHEMBL895388

SCHEMBL895388

O=[C]COC1c2ccccc2-c2ccccc21

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 2/20 0.38
CA1 P00915 1/20 0.37
CA2 P00918 1/20 0.37
POLB P06746 1/20 0.36
ACHE P22303 2/20 0.34
BCHE P06276 1/20 0.34
HDAC3 O15379 1/20 0.33
HDAC4 P56524 1/20 0.33
HDAC7 Q8WUI4 1/20 0.33
HDAC8 Q9BY41 1/20 0.33
HDAC6 Q9UBN7 1/20 0.33
HDAC9 Q9UKV0 1/20 0.33
HDAC5 Q9UQL6 1/20 0.33
NCOR2 Q9Y618 1/20 0.33
GPR3 P46089 1/20 0.33
RET P07949 1/20 0.33
CYP1A2 P05177 1/20 0.33
TSHR P16473 1/20 0.33
MAPT P10636 1/20 0.32
CHRM2 P08172 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21951947 0.74 HTR2A (0.48) HTR2ACA1CA2POLBACHE
SCHEMBL156272 0.72 POLB (0.39) HTR2ACA1CA2POLBACHE
SCHEMBL10447563 0.72 ACHE (0.46) HTR2ACA1CA2POLBACHE
SCHEMBL5732470 0.72 HTR2A (0.38) HTR2ACA1CA2POLBACHE
SCHEMBL9396561 0.71 CYP1A2 (0.46) POLBHDAC3HDAC4HDAC7HDAC8
SCHEMBL5749933 0.69 HTR2A (0.48) HTR2ACA1CA2ACHEBCHE
SCHEMBL16328281 0.69 POLB (0.50) HTR2APOLBACHEBCHEHDAC3
SCHEMBL5745828 0.69 HTR1B (0.44) HTR2AACHEBCHEGPR3RET
SCHEMBL73176 0.68 HTR2A (0.52) HTR2ACA1CA2POLBHDAC3
SCHEMBL16708761 0.68 ALDH1A1 (0.40) HTR2ACA1CA2POLBACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210061893-A1 Diagnostic Kit PHOENIX PHARMACEUTICALS, INC. (US) 2021-03-04 US disclosed
US-10836812-B2 Phoenixin peptides PHOENIX PHARMACEUTICALS, INC. (US) 2020-11-17 US disclosed
EP-2714717-B1 PHOENIXIN PEPTIDES PHOENIX PHARMACEUTICALS INC (US) 2017-07-05 EP disclosed
US-20170145083-A1 Phoenixin Peptides PHOENIX PHARMACEUTICALS, INC. (US) 2017-05-25 US disclosed
US-9534045-B2 Phoenixin peptides PHOENIX PHARMACEUTICALS, INC. (US) 2017-01-03 US disclosed
US-20150322141-A1 Phoenixin Peptides PHOENIX PHARMACEUTICALS, INC. (US) 2015-11-12 US disclosed
US-9018350-B2 Phoenixin peptides PHOENIX PHARMACEUTICALS, INC. (US) 2015-04-28 US disclosed
US-20140163202-A1 Phoenixin Peptides PHOENIX PHARMACEUTICALS, INC. (US) 2014-06-12 US disclosed
US-8586542-B2 Small molecule apoptosis promoters JOYANT PHARMACEUTICALS, INC. (US) 2013-11-19 US disclosed
US-20130281385-A1 SMALL MOLECULE APOPTOSIS PROMOTERS JOYANT PHARMACEUTICALS, INC. 2013-10-24 US disclosed
US-20050203015-A1 Angiogenesis regulation system PHOENIX PHARMACEUTICALS, INC. 2005-09-15 US disclosed
US-6835806-B2 Stable water soluble polypeptides which are potent inhibitors of endothelial cell proliferation and of angiogenesis. PHOENIX PHARMACEUTICALS, INC. 2004-12-28 US disclosed
US-20020111461-A1 LOW MOLECULAR WEIGHT PEPTIDOMIMETIC GROWTH HORMONE SECRETAGOGUES SOMERS TODD C (US) 2002-08-15 US disclosed
EP-1015479-A4 COMBINATORIAL LIBRARIES OF PEPTIDOMIMETIC MACROCYCLES AND PROCESSES THEREFOR LILLY CO ELI (US) 2002-07-24 EP disclosed
US-20020058620-A1 Cell growth regulation system PHOENIX PHARMACEUTICALS, INC. (US) 2002-05-16 US disclosed
EP-0792289-B1 LOW MOLECULAR WEIGHT PEPTIDOMIMETIC GROWTH HORMONE SECRETAGOGUES GENENTECH INC (US) 2000-07-12 EP disclosed
EP-1015479-A1 COMBINATORIAL LIBRARIES OF PEPTIDOMIMETIC MACROCYCLES AND PROCESSES THEREFOR ELI LILLY AND COMPANY (US) 2000-07-05 EP disclosed
EP-0999220-A2 Low molecular weight peptidomimetic growth hormone secretagogues Genentech, Inc. (US) 2000-05-10 EP disclosed
US-6034216-A Low molecular weight peptidomimetic growth hormone secretagogues GENENTECH INC. (US) 2000-03-07 US disclosed
WO-1998046631-A1 COMBINATORIAL LIBRARIES OF PEPTIDOMIMETIC MACROCYCLES AND PROCESSES THEREFOR ELI LILLY AND COMPANY (US) 1998-10-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130281385-A1 SMALL MOLECULE APOPTOSIS PROMOTERS BID, BAD, BAX HTR2A 4241/4885CA1 2899/4885CA2 3945/4885
US-20020111461-A1 LOW MOLECULAR WEIGHT PEPTIDOMIMETIC GROWTH HORMONE SECRETAGOGUES GHSR, GHRHR, IGFBP1 HTR2A 521/4885CA1 3802/4885CA2 1935/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.